アジア、ヨーロッパ、中東、アフリカの裂肛および痔核治療市場をけん引する要因には、痔核＆裂肛の発生率の増加、座りがちな生活習慣の拡大、不健康な食習慣、および便秘の有病率の増加などがあります。一方で、代替治療療法の存在、意識の欠如、恥ずかしさの感情が、市場の成長抑制要因となる可能性があります。さらに、未開拓の市場に参入するプレーヤーが、アジア、ヨーロッパ、中東、アフリカの肛門裂傷および痔核治療市場に有利な成長機会を生み出すことが期待されます。
裂肛裂肛は、歯状線の下の遠位肛門管の粘膜内層の線状の裂傷です。一方、痔は肛門管の静脈が腫れた状態です。痔核＆裂肛は、かゆみ、痛み、出血などの同様の症状を引き起こします。静脈の腫れは痔核の原因となりますが、肛門の内膜の裂傷は裂肛の原因となります。痔核は、肛門の周囲の皮膚の下（外痔核）または直腸の内側（内痔核）に発生する可能性があります。裂肛は、肛門内膜の小さな切り傷または裂傷です。皮膚のひび割れは、排便中および排便後に激しい痛みと鮮血出血を引き起こします。世界の裂肛および痔核治療市場の成長を促す要因は、食事中の繊維摂取量の減少と相まって、座りがちな生活習慣の定着です。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENCE OF HEMORRHOIDS AND ANAL FISSURES
4.2.2 RISING ADOPTION OF SEDENTARY LIFESTYLES AND UNHEALTHY EATING HABITS
4.2.3 INCREASING PREVALENCE OF CONSTIPATION
4.3 RESTRAINTS
4.3.1 ALTERNATE TREATMENT THERAPIES
4.3.2 SOCIAL STIGMA AND LACK OF AWARENESS
4.4 OPPORTUNITIES
4.4.1 ENTERING UNTAPPED MARKETS
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 ENGAGEMENT & DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES FOLLOW-UPS
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE MARKET
6 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY TREATMENT TYPE
6.1 INTRODUCTION
6.2 ANAL FISSURE
6.2.1 MEDICATION
6.2.1.1 TOPICAL NITROLGYLECRIN
6.2.1.2 CALCIUM CHANNEL BLOCKERS
6.2.1.3 STOOL SOFTENERS
6.2.1.4 OTHERS
6.2.2 SURGERY
6.3 HEMORRHOIDS
6.3.1 MEDICATION
6.3.2 SURGERY
7 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
7.1 INTRODUCTION
7.2 ORAL
7.3 TOPICAL
7.4 OTHERS
8 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
8.1 INTRODUCTION
8.2 RETAIL PHARMACIES
8.3 E-COMMERCE
8.4 OTHERS
9 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY END-USER
9.1 INTRODUCTION
9.2 HOSPITALS & CLINICS
9.3 AMBULATORY SURGICAL CENTERS (ASCS)
9.4 OTHERS
10 ASIA, EUROPE, MIDDLE EAST, AND AFRICA ANAL FISSURE & HEMORRHOIDS TREATMENT MARKET, BY REGION
10.1 INTRODUCTION
10.2 EUROPE
10.2.1 GERMANY
10.2.2 FRANCE
10.2.3 UK
10.2.4 ITALY
10.2.5 SPAIN
10.2.6 AUSTRIA
10.2.7 REST OF EUROPE
10.3 ASIA
10.3.1 JAPAN
10.3.2 CHINA
10.3.3 INDIA
10.3.4 REST OF ASIA
10.4 MIDDLE EAST & AFRICA
10.4.1 SAUDI ARABIA
10.4.2 UNITED ARAB EMIRATES
10.4.3 QATAR
10.4.4 AFRICA
10.4.5 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPETITIVE BENCHMARKING
11.3 MAJOR GROWTH STRATEGY IN THE ASIA, EUROPE, MIDDLE EAST & AFRICA ANAL FISSURE AND HAEMORRHOIDS TREATMENT MARKET
11.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE MARKET
11.5 KEY DEVELOPMENTS & GROWTH STRATEGIES
11.5.1 MERGER & ACQUISITIONS
11.6 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO
11.6.1 SALES (USD MILLION), 2020
11.6.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2020
12 COMPANY PROFILES
12.1 ABBOTT LABORATORIES
12.1.1 COMPANY OVERVIEW
12.1.2 FINANCIAL OVERVIEW
12.1.3 PRODUCTS/SERVICES OFFERED
12.1.4 KEY DEVELOPMENTS
12.1.5 SWOT ANALYSIS
12.1.6 KEY STRATEGIES
12.2 BAYER AG
12.2.1 COMPANY OVERVIEWS
12.2.2 FINANCIAL OVERVIEW
12.2.3 PRODUCTS/SERVICES OFFERED
12.2.4 KEY DEVELOPMENTS
12.2.5 SWOT ANALYSIS
12.2.6 KEY STRATEGIES
12.3 COOK MEDICAL
12.3.1 COMPANY OVERVIEW
12.3.2 FINANCIAL OVERVIEW
12.3.3 PRODUCTS/SERVICES OFFERED
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIES
12.4 TROIKAA PHARMACEUTICALS LTD
12.4.1 COMPANY OVERVIEW
12.4.2 FINANCIAL OVERVIEW
12.4.3 PRODUCTS/SERVICES OFFERED
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIES
12.5 TAJ PHARMACEUTICALS LIMITED
12.5.1 COMPANY OVERVIEW
12.5.2 FINANCIAL OVERVIEW
12.5.3 PRODUCTS/SERVICES OFFERED
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIES
12.6 ABBVIE INC
12.6.1 COMPANY OVERVIEW
12.6.2 FINANCIAL OVERVIEW
12.6.3 PRODUCTS OFFERED
12.6.4 KEY DEVELOPMENTS
12.6.5 SWOT ANALYSIS
12.6.6 KEY STRATEGIES
12.7 KYOWA KIRIN INTERNATIONAL PLC
12.7.1 COMPANY OVERVIEW
12.7.2 FINANCIAL OVERVIEW
12.7.3 PRODUCTS OFFERED
12.7.4 KEY DEVELOPMENTS
12.7.5 SWOT ANALYSIS
12.7.6 KEY STRATEGIES
12.8 INTEGRA LIFESCIENCES CORPORATION
12.8.1 COMPANY OVERVIEW
12.8.2 FINANCIAL OVERVIEW
12.8.3 PRODUCTS OFFERED
12.8.4 KEY DEVELOPMENTS
12.8.5 SWOT ANALYSIS
12.8.6 KEY STRATEGIES
12.9 BOSTON SCIENTIFIC CORPORATION
12.9.1 COMPANY OVERVIEW
12.9.2 FINANCIAL OVERVIEW
12.9.3 PRODUCTS OFFERED
12.9.4 KEY DEVELOPMENTS
12.9.5 SWOT ANALYSIS
12.9.6 KEY STRATEGIES
12.10 MEDTRONIC PLC
12.10.1 COMPANY OVERVIEW
12.10.2 FINANCIAL OVERVIEW
12.10.3 PRODUCTS OFFERED
12.10.4 KEY DEVELOPMENTS
12.10.5 SWOT ANALYSIS
12.10.6 KEY STRATEGIES
13 APPENDIX
13.1 REFERENCES
13.2 RELATED REPORTS
